Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Biosergen ABOSTO:BIOSGN 18 EBITDA Margin % is 0.00% as of Dec. 2025. GuruFocus rates OSTO:BIOSGN with a GF Score™ of 18/100. Among 941 Biotechnology companies, Biosergen AB ranks worse than 106269.82% on this metric.
EBITDA Margin % is calculated as EBITDA divided by its Revenue. Biosergen AB's EBITDA for the
three
months ended in Dec. 2025 was kr-12.49 Mil. Biosergen AB's Revenue for the
three
months ended in Dec. 2025 was kr0.00 Mil. Therefore, Biosergen AB's EBITDA margin for the quarter that ended in Dec. 2025 was 0.00%.
Biosergen AB (OSTO:BIOSGN) EBITDA Margin % Explanation
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
Biosergen AB EBITDA Margin % Related Terms
Biosergen AB EBITDA Margin % Historical Data
* Premium members only.
The historical data trend for Biosergen AB's EBITDA Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
OSTO:BIOSGN vs VRTX, REGN, RVMD: EBITDA Margin % Comparison
For the Biotechnology subindustry, Biosergen AB's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Biosergen AB EBITDA Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Biosergen AB's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where Biosergen AB's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Biosergen AB (OSTO:BIOSGN) has a EBITDA Margin % of 0.00% as of Dec. 2025. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Biosergen AB and its competitors. According to the industry distribution chart, Biosergen AB ranks #999999 out of 941 companies in the Biotechnology industry.
Is Biosergen AB's EBITDA Margin % too high?
Biosergen AB's current EBITDA Margin % is 0.00%. Based on the distribution chart, Biosergen AB ranks #999999 out of 941 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Biosergen AB has a GF Score™ of 18/100, reflecting its overall financial health beyond just this single metric.
How does Biosergen AB's EBITDA Margin % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Biosergen AB ranks #999999 out of 941 companies for EBITDA Margin %. This places Biosergen AB in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Biotechnology company?
A good EBITDA Margin % depends on the Biotechnology industry context. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Biosergen AB and its competitors. Biosergen AB's current EBITDA Margin % is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Biosergen AB stock overvalued right now?
Biosergen AB (OSTO:BIOSGN) has a current EBITDA Margin % of 0.00%. The current EBITDA Margin % is 0.00%. Biosergen AB's overall GF Score™ is 18/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Biosergen AB (OSTO:BIOSGN), the current EBITDA Margin % is 0.00% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Biosergen AB is a clinical stage biotechnology company advancing the treatment of life-threatening fungal infections. Biosergen' s mission is to develop the drug candidate BSG005 into a superior antifungal therapy with broader efficacy and improved safety over existing treatments. BSG005 potential is to eliminate fungal infections rather than just slowing their growth, reducing the risk of resistance.
18GF Score
Get the complete analysis for OSTO:BIOSGN
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
OSTO:BIOSGN has been successfully added to your 
